POOLBEG PHARMA PLC - POLBF STOCK NEWS

Poolbeg Pharma has released its Annual Report and AGM notice for the period ending December 31, 2022. Shareholders can access the report and accompanying documents through the Company’s website. The Annual General Meeting is scheduled for May 11, 2023, in London. Poolbeg specializes in developing innovative treatments for infectious diseases, particularly in the wake of the COVID-19 pandemic, which has created a rapidly growing market expected to surpass $250 billion by 2025. The company employs a disciplined portfolio approach for drug development and includes assets from hVIVO plc, enhancing its capabilities in clinical trials. Key assets include POLB 001 for severe influenza, POLB 002 for respiratory viruses, and POLB 003 for Melioidosis.

Poolbeg Pharma Plc (AIM:POLB)(OTCQB:POLBF) announced its audited results for the year ending December 31, 2022, showcasing a solid cash balance of £16.2 million and a €2.3 million non-dilutive funding for its Oral Vaccine Platform.

The company achieved significant milestones with its lead candidate POLB 001, demonstrating safety and efficacy in a human challenge trial for severe influenza. Additionally, POLB 001 is being expanded as a treatment for Cytokine Release Syndrome, with trial initiation anticipated in H1 2024. Poolbeg is also advancing AI programs for RSV and influenza drug discovery while diversifying its pipeline with new candidates.

Poolbeg Pharma has announced the strategic expansion of POLB 001 into oncology, filing a new patent application to protect its use in CAR T cell therapy. The findings suggest that POLB 001 could help reduce the severe side effects associated with cytokine release syndrome (CRS) in CAR T cell patients. With CAR T cell therapies being crucial in treating cancer, especially blood cancers, the market is projected to grow significantly. The company aims to initiate clinical trials in CAR T cell patients in 2024, capitalizing on a significant market opportunity and advancing its long-term objectives to unlock the full potential of POLB 001.

Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) announced positive initial results from the POLB 001 LPS human challenge trial, showing a marked reduction in inflammatory responses compared to placebo. The trial, which included 36 healthy volunteers, demonstrated a clear dose-response relationship and was well tolerated, with no serious adverse events. Full data is expected in Q2 2023, further supporting POLB 001's potential as a treatment for severe influenza.

Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) has identified new potential drug candidates for Respiratory Syncytial Virus (RSV) through its collaboration with OneThree Biotech. This marks the first instance of RSV drug candidates being identified using an Artificial Intelligence (AI) program. The candidates are prioritized based on existing Phase I clinical data to reduce risk, aligning with Poolbeg's capital-efficient development strategy. The urgent need for effective RSV treatments is highlighted as current hospitalizations among young children reach alarming levels.

Poolbeg Pharma has acquired an exclusive license from InsuCaps to utilize patented microencapsulation and nanoencapsulation oral delivery technologies for treating metabolic syndrome diseases, including diabetes and obesity. The upcoming clinical trial, set to begin in H1 2023, aims to demonstrate the safe oral delivery of GLP-1 agonists, a market projected to reach approximately $22 billion by 2025. Additionally, Prof Brendan Buckley joins Poolbeg's Scientific Advisory Board to assist in clinical development.

Poolbeg Pharma has announced the completion of its Influenza Artificial Intelligence model built by CytoReason, set to deliver outputs in Q2 2023. This AI model leverages unique clinical data from human challenge trials to identify new drug targets for influenza. CytoReason, partnered with leading global pharma companies, enhances Poolbeg's ability to develop treatments more efficiently. The company is focusing on drugs with existing Phase I safety data to expedite clinical trials and potential licensing deals.